Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
This Phase 3b, rollover study will provide participants who completed a Phase 3 valbenazine
(NBI-98854) study open-label access to valbenazine (fixed doses administered once daily) for
the treatment of adults with TD until valbenazine is anticipated to be available commercially
or they complete 72 weeks of treatment. This study will allow enrollment of up to 150
medically stable male and female participants with TD who previously participated in and
completed the NBI-98854-1304 (Kinect 3) or NBI-98854-1402 (Kinect 4) Phase 3 study.